ArticleFunctional & integrative genomics2026
An integrative mutational and network analysis of pancreatic cancer reveals key genes, and signalling pathways.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pancreatic cancer (PC) is one of the most lethal malignancies, with an approximately 5% 5-year survival rate. Understanding the intricate network of interactions among the proteins of key pathways is critical for assessing the PC prognosis. Herein, we have carried out a systematic approach by collecting mutational data of genes involved in 10 PC studies with 6,325 PC samples from cBioPortal. A total of 15,088 genes were obtained, to which a mutational frequency cut-off of > 10 was applied. The 1,617 genes acquired after this filtration. These genes were stratified into five PC tiers (PC-TierII to PC-TierV), with PC-TierI comprising six frequently mutated genes icluding KRAS (73.40%), TP53 (51.20%), SMAD4 (18.70%), TTN (14.20%), CDKN2A (12.40%), MUC16 (6.70%) and PC-TierII including ARID1A (5.60%), RNF43 (5.20%), FLG (5.00%). These genes were then used for pathway enrichment analysis using the EnrichR suite, followed by co-expression interaction analysis via GeneMANIA. ACVR1B, KRAS, RBBP8, SMAD4, STK11, and TP53 were predicted to be associated with the PC (OMIM ID: 260350). PC has lower KRAS mutation counts closely related to ovarian and uterus cancers and top KRAS mutations are KRAS
Indexed as
Identifiers
42277390What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.